Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine
Authors:
- Paul BastardPBPaul Bastard
- Eleftherios MichailidisEMEleftherios Michailidis
- Hans-Heinrich HoffmannHHHans-Heinrich Hoffmann
- Marwa ChbihiMCMarwa Chbihi
- Tom Le VoyerTVTom Le Voyer
- Jérémie RosainJRJérémie Rosain
- Quentin PhilippotQPQuentin Philippot
- Yoann SeeleuthnerYSYoann Seeleuthner
- Adrian GervaisAGAdrian Gervais
- Marie MaternaMMMarie Materna
- Patricia Mouta Nunes de OliveiraPOPatricia Mouta Nunes de Oliveira
- Maria de Lourdes S. MaiaMMMaria de Lourdes S. Maia
Top Cited Papers
Open Access
- 5 February 2021
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
Abstract
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.Keywords
Funding Information
- Howard Hughes Medical Institute
- The Rockefeller University
- St. Giles Foundation
- National Institutes of Health (R01AI088364)
- National Center for Advancing Translational Sciences
- National Institutes of Health (UL1 TR001866)
- Emergent Ventures
- George Mason University
- Yale Center for Mendelian Genomics
- National Human Genome Research Institute (UM1HG006504, U24HG008956)
- French National Research Agency (ANR-10-IAHU-01)
- Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID)
- French Foundation for Medical Research (EQU201903007798)
- French Foundation for Medical Research
- French National Research Agency
- ANRS-COV05
- Square Foundation
- Grandir–Fonds de Solidarité pour l’Enfance
- SCOR Corporate Foundation for Science
- Institut National de la Santé et de la Recherche Médicale
- University of Paris
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Institut National de la Santé et de la Recherche Médicale
- Imagine Institute
- Fondation Bettencourt Schueller
- French Foundation for Medical Research (EA20170638020)
- Imagine Institute
- Fondation Bettencourt Schueller
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (1R01AI124690)
This publication has 53 references indexed in Scilit:
- STAT2 deficiency and susceptibility to viral illness in humansProceedings of the National Academy of Sciences, 2013
- Identification and Characterization of the Host Protein DNAJC14 as a Broadly Active Flavivirus Replication ModulatorPLOS Pathogens, 2011
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Case of Yellow Fever Vaccine–Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES GenesThe Journal of Infectious Diseases, 2008
- Anti-Interferon Autoantibodies in Autoimmune Polyendocrinopathy Syndrome Type 1PLOS Medicine, 2006
- Hepatitis and death following vaccination with 17D-204 yellow fever vaccineThe Lancet, 2001
- Role of the Intracellular Domain of the Human Type I Interferon Receptor 2 Chain (IFNAR2c) in Interferon SignalingJournal of Biological Chemistry, 2000